Mesoblast Ltd, also known as MESO, is a leading developer of cellular medicines. The company, incorporated in 2004 and based in Melbourne, Australia, is listed on the Australian Securities Exchange (ASX) and on the Nasdaq Global Market in the United States.
Mesoblast has a strong development portfolio comprising disease-modifying products, all of which are based on its proprietary mesenchymal lineage cell technology. These cells provide a unique mechanism of action by releasing soluble molecules that act locally or systemically to dampen inflammation, promote tissue repair, and boost immune system versatility, offering potential therapeutic benefits to a wide range of severe and life-threatening inflammatory conditions.
Perhaps most prominently, MESO has significantly invested in the research and development of regenerative medicine for chronic cardiovascular diseases, immune-mediated inflammatory diseases, and specific oncology diseases. For example, their lead product candidate, Remestemcel-L, is an anti-inflammatory solution currently in Phase 3 trials for the treatment of graft-versus-host disease and developmental in children.
Furthermore, the company has collaborations with significant global entities. It has a partnership with JCR Pharmaceuticals Co. Ltd for the development and commercialization of the TEMCELL HS Inj., a treatment for acute graft versus host disease in Japan, and with Tasly Pharmaceutical Group to offer cardiovascular products in China.
Despite the pioneering work and promising therapies, Mesoblast had faced some setbacks, such as the prevention of marketing approval by the US Food and Drug Administration for the pediatric graft-versus-host disease treatment. However, the company remains optimistic about the potential of their innovative medicinal practices.
Mesoblast's vision reflects a commitment to leverage their powerful and versatile cellular technology to target some of humankind's most severe diseases, save lives, and improve patient quality of life. Its impact on the healthcare and biotechnology industry is profound, pushing the frontier of traditional treatments and opening new avenues of cellular and regenerative medicine. Overall, the company has positioned itself at the forefront of cellular medicine, promising more advanced and efficacious therapies in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Mesoblast Limited has been awarded the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards, recognizing its successful transition to a commercial-stage biotechnology company. This achievement follows the U.S. launch of Ryoncil® (remestemcel-L-rknd), the first FDA-approved mesenchymal stromal cell therapy. Dr. Silviu Itescu, Mesoblast's CEO, highlighted that the Ryoncil launch has created a strong commercial foundation, enabling patient access to a life-changing product and setting the stage for future growth and shareholder value.
Mesoblast (ASX:MSB) shares have seen a significant 355% gain over three years but are currently trading below their highs after a weaker recent year, prompting questions about its valuation relative to current sales. Despite being loss-making, the market values Mesoblast at a premium P/S ratio of 12.4x, higher than the industry average, largely due to expectations surrounding future product commercialization. Analysts' consensus suggests the stock could be undervalued by 52%, contingent on successful market penetration for products like rexlemestrocel-L and Ryoncil.

Mesoblast (ASX:MSB) is transitioning from an R&D focus to commercial rollout after its first product, Ryoncil, launched and generated US$115 million in sales. The company sees this as a "defining and transformative point" with further products in development for chronic low back pain and adult graft-versus-host disease. Other biotech companies, EBR Systems (ASX:EBR) and Syntara (ASX:SNT), faced challenges with sales and study setbacks, respectively, while Pathkey.AI (ASX:PKY) will use AI to evaluate Paradigm Biopharmaceuticals' (ASX:PAR) stalled knee osteoarthritis program.

Mesoblast Limited hosted a key opinion leader webinar featuring Dr. Susan Prockop, who discussed Ryoncil (remestemcel-L-rknd) as a new treatment paradigm for acute graft-versus-host disease (aGvHD) in pediatric patients, specifically its use as a first-line therapy after steroids. The webinar highlighted case studies and pivotal trial results, positioning Ryoncil as the first FDA-approved mesenchymal stromal cell (MSC) therapy for steroid-refractory acute GvHD. Mesoblast continues to develop additional cell therapies for other inflammatory diseases and chronic conditions.
Mesoblast recently hosted a key opinion leader webinar featuring Dr. Susan Prockop, who discussed Ryoncil as a first-line treatment for acute graft-versus-host disease in pediatric patients after steroid therapy. Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. The announcement is a marketing update for shareholders, highlighting the company's promotion of an approved product rather than new financial or regulatory news.